



Press Release

STADA is in top 3% on pharma sustainability, Morningstar Sustainalytics assessment confirms

- STADA is ranked in top 3% of its pharmaceutical peer group in terms of Environmental, Social and Governance (ESG) Risk Ratings, according to the latest assessment by independent agency Morningstar Sustainalytics
- Improved ranking reflects STADA's strong risk management, as well as numerous local ESG initiatives such as the STADA Health Report survey of health awareness and opinions in 22 European countries
- STADA CEO Peter Goldschmidt: "This external confirmation from a leading independent agency recognizes the ever sharper focus within our organization on sustainable healthcare, fully in line with our purpose that we have fulfilled for more than 130 years: Caring for People's Health as a Trusted Partner."

Bad Vilbel, Germany – 17 November 2025 – STADA continued progress on sustainability has been confirmed. The leading healthcare and pharmaceuticals company specializing in Consumer Healthcare, Generics and Specialty pharmaceuticals is ranked within the top 3% of its pharmaceutical peer group in terms of Environmental, Social and Governance (ESG) Risk Ratings, according to the latest assessment by independent agency Morningstar Sustainalytics.

By reducing its ESG Risk rating by a further 1.7 points to 16.4, STADA further reinforced the group's ranking in the 'Low Risk' category. "The company's overall management of material ESG issues is strong," Morningstar Sustainalytics confirmed, highlighting robust management accountability and a "very strong" environmental policy and ESG reporting.

Executive Board: Peter Goldschmidt (CEO) / Simone Berger / Miguel Pagan Fernandez / Boris Döbler
Chairman of the Supervisory Board: Dr. Günter von Au



As such, STADA holds a position among the top 3% of all companies within Morningstar Sustainalytics' Pharmaceuticals sub-category that covers more than 420 assessed companies.

Morningstar Sustainalytics' ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks. This multi-dimensional way of measuring ESG risk combines the concepts of management and exposure to arrive at an assessment of ESG risk, i.e., a total unmanaged ESG risk score or the ESG Risk Rating, that is comparable across all industries. The ESG Risk Ratings provide a quantitative measure of unmanaged ESG risk and distinguish between five levels of risk: negligible, low, medium, high and severe. STADA is ranked among the top 16% of the global universe of more than 14,000 organizations evaluated by Morningstar Sustainalytics.

Peter Goldschmidt, Chief Executive Officer of STADA, commented: "This external confirmation from a leading independent agency recognizes the ever sharper focus within our organization on sustainable healthcare, fully in line with our purpose that we have fulfilled for more than 130 years: Caring for People's Health as a Trusted Partner."

STADA Health Report: Comprehensive information for 22 countries

A key means by which STADA delivers on this purpose is by providing comprehensive health-related information and insights through the findings of the STADA Health Report, an industry-leading survey 27,000 adults across 22 European countries. Topics explored in the 2025 edition include trust in healthcare professionals, gaps in preventive healthcare, acceptance of artificial-intelligence tools, motivations to self-care, and the prevalence of burnout.

Insights from the STADA Health Report are shared widely with stakeholders on a national basis, in accordance with STADA's approach of making a difference at a local level. Among



numerous ESG initiatives undertaken at national or local level, as detailed in the [STADA Sustainability Report](#), are:

Germany: By donating 2 cents for every pack of STADA OTC products sold, STADA has been able to give the German Red Cross more than €500,000 to support humanitarian projects.

Italy: EG STADA Italy was in September 2025 recognized by Forbes for its project *Tour della Salute*, a travelling event focused on prevention and the adoption of healthy lifestyles that in 2024 visited 15 cities and conducted 6,454 free health screenings. Forbes awarded the *Tour della Salute* as the Best Project for Supporting Community Health, a category that honors efforts contributing significantly to well-being by addressing major health challenges.

Romania: The supply-chain hub that STADA constructed in Turda recently released its 1,000th product batch. Following initial shipments in late-2024, release of essential medicines such as atorvastatin, olmesartan and pantoprazole from the site has stepped up, contributing to sustainable medicines supply across Europe.

Ireland: revising logistics for hospital and pharmacy customers resulted in a reduction of 0.25kg CO₂ per pack, representing a 70% reduction in emissions by Ireland's largest supplier of generic medicines. Despite increasing product volumes, 45 tons of CO₂ were prevented.

Serbia: Hemofarm and the Hemofarm Foundation, in partnership with Serbia's Ministry of Health and patient organizations, created the "Most Important Call in Life Campaign" to promote organ donation via cinema screenings, billboards and media outreach, leading to 15 lives being saved through organ transplants.

Bulgaria and Slovakia: Reforestation projects have seen STADA's local affiliates plant thousands of trees, thus supporting environmental equilibrium across multiple sites with an aim of planting 1 million trees across the "Plant a tree, make a home" initiative.

Executive Board: Peter Goldschmidt (CEO) / Simone Berger / Miguel Pagan Fernandez / Boris Döbler
Chairman of the Supervisory Board: Dr. Günter von Au



Vietnam: Medicines and health-screening checks have been provided to 500 people, largely in rural and deprived areas.

At a regional, national and international level, STADA is fully committed to delivering on ESG by Caring for People's Health as a Trusted Partner.

Copyright ©2025 Sustainalytics, a Morningstar company. All rights reserved.

This press release includes information and data provided by Sustainalytics and/or its content providers. Information provided by Sustainalytics is not directed to or intended for use or distribution to India-based clients or users and its distribution to Indian resident individuals or entities is not permitted. Morningstar/Sustainalytics accepts no responsibility or liability whatsoever for the actions of third parties in this respect. Use of such data is subject to conditions available at www.sustainalytics.com/legal-disclaimers.

About STADA Arzneimittel AG

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in over 100 countries. In financial year 2024, STADA achieved group sales of € 4,059 million and adjusted constant-currency earnings before interest, taxes, depreciation and amortization (adj. cc EBITDA) of € 886 million. As of 31 December 2024, STADA employed 11,649 people worldwide.

Additional information for journalists

STADA Arzneimittel AG - Media Relations

Stadastrasse 2-18, 61118 Bad Vilbel - Germany

Phone: +49 (0) 6101 603-165

E-Mail: press@stada.de

Or visit us via our website at <https://www.stada.com/media/newsroom>

Follow [@StadaGroup](#) on LinkedIn

Additional information for capital market participants

STADA Arzneimittel AG - Investor & Creditor Relations

Stadastrasse 2-18, 61118 Bad Vilbel – Germany

Phone: +49 (0) 6101 603-4689

E-mail: ir@stada.de

Or visit us via our website at <https://www.stada.com/investor-relations/>

Executive Board: Peter Goldschmidt (CEO) / Simone Berger / Miguel Pagan Fernandez / Boris Döbler

Chairman of the Supervisory Board: Dr. Günter von Au